UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): December 17, 2013
Cleveland BioLabs, Inc.
(Exact Name of Issuer as Specified in Charter)
DELAWARE |
001-32954 |
20-0077155 |
(State or Other Jurisdiction of
Incorporation or Organization) | (Commission File Number) | (I.R.S. Employer Identification
Number) |
73 High Street
Buffalo, NY |
14203 |
| (Address of Principal Executive Offices) | (Zip Code) |
(716) 849-6810
(Registrant's Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 18, 2013, Cleveland BioLabs, Inc. (the "Company") issued a press release announcing that Jean Viallet, M.D., Chief Development Officer, has resigned from the Company to pursue other opportunities. Dr. Viallet will remain with the Company through January 3, 2014. A copy of the Company's press release is filed herewith as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibit Number |
| Description |
99.1 |
| Press Release dated December 18, 2013. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | Cleveland BioLabs, Inc.
|
| Date: December 18, 2013 | | By: /s/ YAKOV KOGAN
Name: Yakov Kogan, Ph.D., M.B.A.
Title: Chief Executive Officer |
